Idiopathic hypersomnia is a neurological sleep disorder characterised by excessive daytime sleepiness despite getting a full ...

Irish biopharmaceutical company Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 ...

Alkermes plc ALKS announced that it has initiated the phase II Vibrance-3 study, evaluating the novel, investigational and ...

Alkermes (ALKS) announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...

With idiopathic hypersomnia, it’s hard to get to a diagnosis, much less an effective treatment. Learn what you need to know to take control of your care.

Searching for effective treatment options for 'Hypersomnia symptom'? This page is a valuable resource, featuring a complete guide to the latest medications-both generic and branded-ideal for ...

These quiz questions about idiopathic hypersomnia (IH) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your physician colleagues.

Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic ...

There remains high unmet need for the idiopathic hypersomnia community, as evidenced by a recent survey conducted by the Sleep Consortium1 in which more than 90% of patients surveyed indicated ...

There remains high unmet need for the idiopathic hypersomnia community, as evidenced by a recent survey conducted by the Sleep Consortium 1 in which more than 90% of patients surveyed indicated ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025ORX750 Phase 2a ...

Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and ...